Infinity minus one: shares plummet as spiky saridegib fails in pancreatic cancer
This article was originally published in Scrip
Executive Summary
Infinity Pharmaceuticals has halted a Phase II trial of one of its key clinical programmes – for its experimental pancreatic cancer drug saridegib (also known as IPI-926), a Hedgehog pathway inhibitor, being studied in combination with gemcitabine. An interim analysis showed that there was better survival in the control arm of the trial than in the saridegib treatment arm. Infinity's shares dropped $3.97, or 40%, to close at $5.97 on 27 January.